{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:01:51Z","timestamp":1790791311825,"version":"4.1.0"},"reference-count":70,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple recurrent somatic mutations have recently been identified in association with myeloproliferative neoplasms (MPN). This meta-analysis aims to assess the pooled prevalence of TET2 gene mutations among patients with MPN. Six databases (PubMed, Scopus, ScienceDirect, Google Scholar, Web of Science and Embase) were searched for relevant studies from inception till September 2020, without language restrictions. The eligibility criteria included BCR-ABL-negative MPN adults with TET2 gene mutations. A random-effects model was used to estimate the pooled prevalence with 95% confidence intervals (CIs). Subgroup analyses explored results among different continents and countries, WHO diagnostic criteria, screening methods and types of MF. Quality assessment was undertaken using the Joanna Briggs Institute critical appraisal tool. The study was registered with PROSPERO (CRD42020212223). Thirty-five studies were included (n = 5121, 47.1% female). Overall, the pooled prevalence of TET2 gene mutations in MPN patients was 15.5% (95% CI: 12.1\u201319.0%, I2 = 94%). Regional differences explained a substantial amount of heterogeneity. The prevalence of TET2 gene mutations among the three subtypes PV, ET and MF were 16.8%, 9.8% and 15.7%, respectively. The quality of the included studies was determined to be moderate\u2013high among 83% of the included studies. Among patients with BCR-ABL-negative MPN, the overall prevalence of TET2 gene mutations was 15.5%.<\/jats:p>","DOI":"10.3390\/cancers13123078","type":"journal-article","created":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T22:00:02Z","timestamp":1624226402000},"page":"3078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"given":"Yuh Cai","family":"Chia","sequence":"first","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-6473","authenticated-orcid":false,"given":"Md Asiful","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Hider","sequence":"additional","affiliation":[{"name":"Department of Population Health, University of Otago, Christchurch 8140, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng Yeong","family":"Woon","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-0220","authenticated-orcid":false,"given":"Muhammad Farid","family":"Johan","sequence":"additional","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosline","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marini","family":"Ramli","sequence":"additional","affiliation":[{"name":"Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5581\/1516-8484.20120035","article-title":"Molecular biology of Philadelphia-negative myeloproliferative neoplasms","volume":"34","author":"Campregher","year":"2012","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tefferi, A., and Elliott, M. (2007). Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Seminars in Thrombosis and Hemostasis, Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-2007-976165"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","article-title":"Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia","volume":"145","author":"Reinig","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chia, Y.C., Islam, M.A., Woon, P.Y., Johan, M.F., Hassan, R., and Ramli, M. (2021). Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology. Genes Dis.","DOI":"10.1016\/j.gendis.2021.01.002"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ajh.23243","article-title":"JAK2 and genomic instability in the myeloproliferative neoplasms: A case of the chicken or the egg?","volume":"87","author":"Scott","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: Disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3324\/haematol.2010.029678","article-title":"Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera","volume":"96","author":"Swierczek","year":"2011","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aromataris, E., and Munn, Z. (2020). Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis, JBI. Available online: https:\/\/synthesismanual.jbi.global.","DOI":"10.46658\/JBIRM-17-01"},{"key":"ref_14","first-page":"173","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms","volume":"44","author":"Ha","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2010.07.006","article-title":"EZH2 mutations: Mutating the epigenetic machinery in myeloid malignancies","volume":"18","author":"Levine","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"562634","DOI":"10.3389\/fneur.2020.562634","article-title":"Prevalence of Headache in Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients","volume":"11","author":"Islam","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ihle, M.A., Fassunke, J., K\u00f6nig, K., Gr\u00fcnewald, I., Schlaak, M., Kreuzberg, N., Tietze, L., Schildhaus, H.-U., B\u00fcttner, R., and Merkelbach-Bruse, S. (2014). Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-13"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.16450","article-title":"ASXL1 mutations, Pevious vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients","volume":"189","author":"Pettersson","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in polycythemia vera: Clinical and molecular correlates","volume":"92","author":"Barraco","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41375-019-0668-5","article-title":"Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis","volume":"34","author":"Bartels","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3324\/haematol.2013.091454","article-title":"Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase","volume":"99","author":"Brecqueville","year":"2014","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00277-018-3563-7","article-title":"Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis","volume":"98","author":"Gill","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_30","first-page":"13","article-title":"Mutation profiles of classic myeloproliferative neoplasms detected by a customized next-generation sequencing-based 50-gene panel","volume":"3","author":"Huang","year":"2020","journal-title":"J. Bio-X Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.21562","article-title":"Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms","volume":"85","author":"Hussein","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation","volume":"23","author":"Panagiota","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","unstructured":"Oppliger Leibundgut, E., Haubitz, M., Burington, B., Ottmann, O.G., Spitzer, G., Odenike, O., McDevitt, M.A., R\u00f6th, A., Snyder, D.S., and Baerlocher, G.M. (2020). Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmoldx.2016.05.006","article-title":"Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation","volume":"18","author":"Magor","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-011-1330-0","article-title":"TET2, ASXL1, IDH1, IDH2, And c-CBL genes in JAK2-and MPL-negative myeloproliferative neoplasms","volume":"91","author":"Besses","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1038\/s41598-017-07057-3","article-title":"Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations","volume":"7","author":"Westman","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","article-title":"Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms","volume":"73","author":"Nischal","year":"2013","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood.2019001861","article-title":"The poor outcome in high molecular risk, hydroxycarbamide-resistant\/intolerant ET is not ameliorated by ruxolitinib","volume":"134","author":"Hamblin","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"929840","DOI":"10.1155\/2013\/929840","article-title":"TET2 mutations in Ph-negative myeloproliferative neoplasms: Identification of three novel mutations and relationship with clinical and laboratory findings","volume":"2013","author":"Patriarca","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2009-01-197525","article-title":"Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms","volume":"114","author":"Leroy","year":"2009","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2012.064683","article-title":"Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow","volume":"97","author":"Schnittger","year":"2012","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Segura-D\u00edaz, A., Stuckey, R., Florido, Y., Gonz\u00e1lez-Mart\u00edn, J.M., L\u00f3pez-Rodr\u00edguez, J.F., S\u00e1nchez-Sosa, S., Gonz\u00e1lez-P\u00e9rez, E., Perdomo, M.N.S., del Mar Perera, M., and de la Iglesia, S. (2020). Thrombotic risk detection in patients with polycythemia vera: The predictive role of DNMT3A\/TET2\/ASXL1 mutations. Cancers, 12.","DOI":"10.3390\/cancers12040934"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis","volume":"147","author":"Song","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bjh.12738","article-title":"TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis","volume":"165","author":"Verger","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_52","first-page":"453","article-title":"Symptom burden and its relationships with risk assessment and gene mutations in patients with primary myelofibrosis","volume":"24","author":"Chunxia","year":"2015","journal-title":"J. Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.leukres.2017.03.013","article-title":"Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis","volume":"58","author":"Guo","year":"2017","journal-title":"Leukemia Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","article-title":"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)","volume":"114","author":"Kosmider","year":"2009","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08556.x","article-title":"TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm","volume":"153","author":"Jardin","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2013.283","article-title":"Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm","volume":"28","author":"Menezes","year":"2014","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Ochoa, M., Toro, P.A.A., and Cardona-Arias, J.A. (2019). Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000\u20132018. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5764-4"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.22212","article-title":"Environmental, Lifestyle, And familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: A user\u2019s manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:19:46Z","timestamp":1760163586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":70,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13123078"],"URL":"https:\/\/doi.org\/10.3390\/cancers13123078","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,20]]}}}